Pressure BioSciences' Ultra High Pressure HUB Platform Highly Effective in Studies to Develop Improved Methods for Food Safety

June 19, 2019 9:32 AM

HUB Platform Plays Critical Role in Innovative Research Studies Designed to Increase Understanding of and Develop Methods for the Prevention of Serious Food-Borne Diseases Caused by E. coli and Listeria SOUTH EASTON, MA / ACCESSWIRE / June 19, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology...

Read more

GreenStar Biosciences Announces Senior Management Addition

June 19, 2019 8:30 AM

VANCOUVER, BC / ACCESSWIRE / June 19, 2019 / GreenStar Biosciences Corp. ("GreenStar" or the "Company") (CSE: GSTR) is pleased to announce that, effective today, Mr. Rahim Rajwani has been appointed as Chief Executive Officer of the Company. Mr. Ralph Olson, the Company's current CEO, will be moving to the role of President of GreenStar. Subject to final board approval, Mr. Rajwani will also join the board of directors of the Company. Leighton...

Read more

Vitro Bio-Pharma 2nd Quarter Ended April 30th 2019 Financial Results of Operations

June 18, 2019 4:10 PM

GOLDEN, CO / ACCESSWIRE / June 18, 2019 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30th 2019 financial results of operations. Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 2nd quarter in Stem Cell Revenues. Vitro Biopharma recorded 2nd quarter revenues of $211,900 vs $125,103 an increase of 69% over the same comparative quarter last year. In addition, Stem Cell...

Read more

GreenStar Biosciences Provides Corporate Update

June 18, 2019 9:00 AM

VANCOUVER, BC / ACCESSWIRE / June 18, 2019 / GreenStar Biosciences Corp. ("GreenStar" or the "Company") (CSE: GSTR) is pleased to provide the following corporate update with respect to the business and prospects of GreenStar Biosciences Corp. GreenStar's current primary business involves the leasing, branding and intellectual property of Cowlitz County Cannabis Cultivation Inc. ("Cowlitz"), a licensed cannabis producer and processor located in...

Read more

Hancock Jaffe Successfully Completes VenoValve Implantation for First-in-Human Study

June 13, 2019 8:31 AM

Six Patients Now Part of First-in-Human Bogota Study IRVINE, CA / ACCESSWIRE / June 13, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted the VenoValve in an additional patient. The procedure very went well and there are no early signs of adverse events. Six out of the ten patients that are to be a part of the initial phase of HJLI's...

Read more

Pressure BioSciences' PCT Platform Prominently Featured in Record Number of Presentations at Major International Science Conference

June 12, 2019 9:27 AM

Scientists from Leading Laboratories in Europe, Asia, Oceania, and North America Highlight the Critical Importance of PBI's Patented PCT System in Cancer and Other Priority Research Areas SOUTH EASTON, MA / ACCESSWIRE / June 12, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-base instruments, consumables, and platform technology solutions to the...

Read more

Hancock Jaffe Announces Pricing of Public Offering of Common Stock

June 12, 2019 9:00 AM

Company Fortifies Balance Sheet Ahead of Key Milestones IRVINE, CA / ACCESSWIRE / June 12, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its public offering of 3,615,622 shares of its common stock at a price to the public of $1.07 per share, for expected total gross proceeds of approximately $3.9 million, before deducting...

Read more

Greenstar Announces Execution of Long Term Cannabis Flower Supply Agreement

June 12, 2019 8:00 AM

VANCOUVER, BC / ACCESSWIRE / June 12, 2019 / Greenstar Biosciences Corp. ("Greenstar" or the "Company") (CSE: GSTR) is pleased to announce that its tenant partner in Washington State, Cowlitz County Cannabis Cultivation, Inc. ("Cowlitz"), has signed a long-term supply agreement with Pat Dullanty, owner and operator of an 18 acre tier 3 outdoor grow facility located at 26425 S Rupp Rd, Cheney, Washington 99001. Pursuant to this new agreement,...

Read more

THC Farmaceuticals Receives Patent Protection in Republic of South Africa For Methods of Producing Antibody- Rich Cannabis and Honeysuckle Plants

June 12, 2019 6:00 AM

THOUSAND OAKS, CA / ACCESSWIRE / June 12, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK: CBDG) today announced that its parent company has been granted patent protection for the South African Patent Application No. 2017/01966 regarding the parent company's Methods of Producing Antibody- Rich Cannabis and Honeysuckle Plants. South African Republic's Patent Office has scheduled publication of this...

Read more

Dyadic to Ring the Nasdaq Closing Bell on June 17, 2019

June 11, 2019 8:50 AM

JUPITER, FL / ACCESSWIRE / June 11, 2019 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scale today announced that its President and Chief...

Read more

Experion Adds Veteran Financial and Business Magnate to Board of Directors with the Appointment of William (Bill) Kenneth Dickie

June 11, 2019 8:30 AM

VANCOUVER, BC / ACCESSWIRE / June 11, 2019 / Experion Holdings Ltd. ("Experion" or the "Company") (TSX-V: EXP), formerly Viridium Pacific Group Ltd., is pleased to announce the appointment of a new member to its Board of Directors. Mr. William (Bill) Kenneth Dickie will join Mr. Jay Garnett, Chief Executive Officer of Experion Holdings Ltd, on the Board of Directors effective June 11, 2019. Mr. Dickie brings substantial financial oversight and...

Read more

Molecular Partners Announces Scientific Leadership Transition After Successful Transformation of Research Organization to Focus on Novel DARPin (R) Therapeutics in Oncology

June 11, 2019 1:00 AM

Pamela A. Trail, Ph.D., to transition from Chief Scientific Officer to strategic consultant; Daniel Steiner, Ph.D., to assume leadership of research organization ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 11, 2019 / Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that Pamela A. Trail, Ph.D., will depart from her role as Chief...

Read more

Hancock Jaffe Reports Early Positive Results from First-In-Human VenoValve Study

June 7, 2019 8:31 AM

Reflux Significantly Reduced in Four out of Five Patients IRVINE, CA / ACCESSWIRE / June 7, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced early positive results from its first-in-human VenoValve Study in Bogota, Colombia. Deep venous reflux has been significantly reduced in 4 out of the first 5 patients that have received VenoValves. Reflux...

Read more

Calmare Therapeutics Receives Favorable Decision From The U.S. Court Of Appeals For The Second Circuit

June 3, 2019 1:35 PM

GEOMC's Petition for Rehearing Denied $10.4 Million Judgment Against Calmare Therapeutics Vacated FAIRFIELD, CT / ACCESSWIRE / June 3, 2019 / Calmare Therapeutics Incorporated, (OTC PINK: CTTC), the pain mitigation company ("Calmare"), has received a favorable decision from the U.S. Court of Appeals for the Second Circuit (the "Court"), which refused to reconsider its March 2019 decision to vacate a $10.4 million judgment against the Company. On...

Read more

Great Bay Bio was Founded to Build a Platform for CMC Technology and Pre Clinical Research and Development of Big Data Services for Innovative Drugs, Dr. Michael Chan as CEO

June 3, 2019 9:35 AM

HONG KONG / ACCESSWIRE / June 3, 2019 / Great Bay Bio, a leading biotechnology company dedicated to innovative drug CMC (Chemistry Manufacturing and Controls) and pre-clinical development of big data service platform, announced its formal establishment in Hong Kong today and the Chairman, Mr. Kingsley Leung is pleased to appoint Mr. Michael Chan as CEO and co-founder of the company on behalf of the board. Dr. Michael Chan has officially assumed...

Read more

AYOXXA Launches the New LUNARIS(TM) Reader Designed to Facilitate Translational Research in Academic and Industrial Laboratories

June 3, 2019 8:20 AM

The new LUNARISTM Reader is a modern and compact state-of-the-art laboratory device designed to address the different needs in academic and industrial environments The availability of two models provides for flexibility by accommodating a range of standard low- to high-throughput formats with readout times of less than 10 minutes for 96 wells Easy-to-use "load and read" handling simplifies the operation of the LUNARISTM Reader ...

Read more

ORYZON to Present First Clinical Data from ALICE Phase IIa Trial with Iadademstat at the 24th Congress of the European Hematology Association

June 3, 2019 8:00 AM

The company will also present at the Jefferies 2019 Global Healthcare Conference MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present preliminary safety and efficacy data from one of its ongoing...

Read more

Pieris Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

May 30, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / May 30, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Stephen Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Jefferies 2019 Healthcare Conference in New York, New York on...

Read more

ORYZON Announces First Patient in the US in ETHERAL-US: A Phase IIa Clinical Trial with Vafidemstat in Alzheimer's Disease

May 29, 2019 8:00 AM

ETHERAL Europe Reached 100 Patients Randomized Last Week MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / May 29, 2019 / Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in the US in its Phase IIa clinical trial with vafidemstat in Alzheimer's disease (AD). The...

Read more

Hancock Jaffe to Present VenoValve Case Management Report at Expert Venous Management Conference on June 7, 2019

May 28, 2019 8:31 AM

Initial Patient Data to be Released on June 7th for First-In-Human VenoValve Study IRVINE, CA / ACCESSWIRE / May 28, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, will report initial data on the first five patients that received VenoValves as part of the first-in-human study in Bogota, Colombia, and will present a case management report at the Expert Venous...

Read more